Business Context and Reporting Period
Company: Alpha Tau Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: May 2026 (Specifically May 8, 2026)
Context: The filing serves to distribute a press release announcing a conference call to discuss interim results from the first three patients treated for recurrent glioblastoma.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to disseminate a press release regarding clinical trial progress rather than a financial report.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The primary update is the progression of clinical activities, specifically the availability of interim results for the first three patients in the recurrent glioblastoma study.
Guidance, Outlook, and Risks
Management Commentary: The Company announced a conference call to discuss interim results from the first three patients treated for recurrent glioblastoma.
Outlook: The filing indicates ongoing clinical evaluation but does not provide specific future financial guidance or operational forecasts.
Risks and Contingencies: The filing includes standard disclaimers stating that the information is furnished and not "filed" under Section 18 of the Exchange Act, limiting liability. No specific new risks or contingencies are detailed in the text provided.
Investor Verification Checklist
- Verify the date and time of the announced conference call to discuss interim results.
- Review the attached Exhibit 99.1 (Press Release) for specific clinical data regarding the first three patients.
- Confirm the status of the recurrent glioblastoma clinical trial in subsequent filings.
- Note that this filing contains no audited financial data or updated financial guidance.